Acute promyelocytic leukaemia (APML)
What is APML?
Acute promyelocytic leukaemia (APML) is a rare sub-type of acute myeloid leukaemia (AML) and is sometimes referred to as AML M31. APML accounts for only 10% of all AML diagnoses.
In APML, immature abnormal neutrophils (a type of white blood cell) known as promyelocytes accumulate in the bone marrow. These immature cells are unable to mature and function like healthy mature white cells. The accumulation of these immature cells in the marrow inhibits normal cell production, which results in lower numbers of blood cells circulating the body.
APML is most commonly associated with a swapping over (translocation) of chromosomes 15 and 17. This causes parts of a gene from each of these chromosomes to join and create a fusion gene called PML/RARA. In some cases, other chromosomes may translocate and cause a variant APML, but this is quite rare.
Acute promyelocytic leukaemia: the basics
How common is APML?
Who gets APML?
What causes APML?
What are the symptoms of APML?
Last updated on May 21st, 2024
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.